These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 38154140)
41. Obstructive sleep apnea may induce orexinergic system and cerebral β-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk? Liguori C; Mercuri NB; Nuccetelli M; Izzi F; Cordella A; Bernardini S; Placidi F Sleep Med; 2019 Apr; 56():171-176. PubMed ID: 30799255 [TBL] [Abstract][Full Text] [Related]
42. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
44. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM; Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642 [TBL] [Abstract][Full Text] [Related]
45. Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. Gao CM; Yam AY; Wang X; Magdangal E; Salisbury C; Peretz D; Zuckermann RN; Connolly MD; Hansson O; Minthon L; Zetterberg H; Blennow K; Fedynyshyn JP; Allauzen S PLoS One; 2010 Dec; 5(12):e15725. PubMed ID: 21209907 [TBL] [Abstract][Full Text] [Related]
46. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217. Bali D; Hansson O; Janelidze S Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843 [TBL] [Abstract][Full Text] [Related]
47. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824 [TBL] [Abstract][Full Text] [Related]
48. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls. Feinkohl I; Schipke CG; Kruppa J; Menne F; Winterer G; Pischon T; Peters O J Alzheimers Dis; 2020; 74(4):1285-1294. PubMed ID: 32176645 [TBL] [Abstract][Full Text] [Related]
49. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455 [TBL] [Abstract][Full Text] [Related]